Brief: Fate Therapeutics Highlights Ipsc-Derived, Off-The-Shelf Car Nk Cell Programs For Multiple Myeloma
10/12/2022 20:07
Dec 10 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS HIGHLIGHTS IPSC-DERIVED, OFF-THE-SHELF
CAR NK
CELL PROGRAMS FOR MULTIPLE MYELOMA AT 2022 ASH ANNUAL MEETING
* FATE THERAPEUTICS - INTERIM PHASE 1 DATA OF FT576
BCMA-TARGETED
PRODUCT CANDIDATE SHOW CLINICAL ACTIVITY IN INITIAL SINGLE-DOSE
ESCALATION COHORTS
* FATE THERAPEUTICS INC - CANDIDATE SHOWS CLINICAL ACTIVITY
IN
INITIAL SINGLE-DOSE ESCALATION COHORTS AS MONOTHERAPY AND IN
COMBINATION WITH DARATUMUMAB
Source text for Eikon: ID:nGNX38nwRq
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview